Liven Pharma Limited (PSX:LIVEN)
Pakistan · Delayed Price · Currency is PKR 32.38
+0.08 (0.25%)
At close: Sep 9, 2026
Liven Pharma Ratios and Metrics
Market cap in millions PKR. Fiscal year is July - June.
Millions PKR. Fiscal year is Jul - Jun.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 8, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| 3,651 | 6,042 | 110 | 185 | 152 | 303 | |
Market Cap Growth | -37.97% | 5370.54% | -40.46% | 21.91% | -49.80% | 127.48% |
Enterprise Value | 3,500 | 6,080 | 349 | 423 | 387 | 535 |
Last Close Price | 32.30 | 55.17 | 7.74 | 13.00 | 10.66 | 21.24 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 8, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
PE Ratio | - | - | 2.65 | - | - | - |
PS Ratio | 36.84 | 47.47 | 0.45 | - | - | - |
PB Ratio | 4.41 | 9.53 | 0.15 | -1.51 | -1.38 | -3.16 |
P/TBV Ratio | 4.46 | 9.66 | 0.15 | - | - | - |
P/FCF Ratio | 19.77 | - | 8.00 | - | - | - |
P/OCF Ratio | 16.83 | - | 8.00 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 8, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
EV/Sales Ratio | 35.31 | 47.77 | 1.42 | - | - | - |
EV/EBITDA Ratio | - | - | 5.37 | - | - | - |
EV/EBIT Ratio | - | - | 8.35 | - | - | - |
EV/FCF Ratio | 18.95 | - | 25.26 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 8, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Debt / Equity Ratio | 0.03 | 0.06 | 0.21 | -1.94 | -2.13 | -2.43 |
Debt / EBITDA Ratio | - | - | 2.35 | - | - | - |
Debt / FCF Ratio | 0.15 | - | 11.37 | - | - | - |
Net Debt / Equity Ratio | -0.18 | 0.04 | 0.18 | -1.94 | -2.13 | -2.43 |
Net Debt / EBITDA Ratio | 0.30 | -0.06 | 2.03 | -111.87 | -79.65 | -110.82 |
Net Debt / FCF Ratio | -0.82 | -1.09 | 9.56 | -104.83 | -104.11 | -34.31 |
Asset Turnover | 0.10 | 0.14 | 0.46 | - | - | - |
Inventory Turnover | 0.70 | 0.90 | - | - | - | - |
Quick Ratio | 2.27 | 0.19 | 0.71 | 0 | 0 | 0 |
Current Ratio | 3.79 | 1.64 | 1.48 | 0 | 0 | 0.00 |
Return on Equity (ROE) | -81.35% | -84.49% | 13.31% | - | - | - |
Return on Assets (ROA) | -33.95% | -35.12% | 4.93% | -6.89% | -7.20% | -6.80% |
Return on Capital Employed (ROCE) | -59.00% | -67.10% | 5.60% | 14.20% | 19.10% | 24.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 8, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Earnings Yield | -19.21% | -9.67% | 37.80% | -6.65% | -9.39% | -4.83% |
FCF Yield | 5.06% | -0.41% | 12.50% | -1.22% | -1.49% | -2.24% |
Buyback Yield / Dilution | -172.01% | -174375.69% | 99.67% | - | - | - |